**Conflict of interest**

All coauthors declare no conflict of interest.

## **Nomenclature**

Directiva 2010/63 UE Real Decreto 53/2013 3Rs principles Normativa D2010/63/EU Guidelines (OECD TG 407 and 408) The European Partnership for Alternative Approaches to Animal Testing (EPAA) Directiva 2010/63/EU The principles of Good Laboratory Practice (GLP) Nanomaterials (NMs) European Directive 2010/63/EU Positron emission tomography (PET) Functional magnetic resonance imaging (fMRI)

## **Author details**

Liliana Anguiano-Robledo1 \*, Claudia C. Calzada-Mendoza1 , Cornelio Barrientos-Alvarado2 and María Elena Hernández-Campos1

\*Address all correspondence to: languianorobledo@yahoo.com.mx

1 Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomás, Delegación Miguel Hidalgo, México City, México

2 Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomás, México City, México

## **References**

funding for animal facilities, have lesser bureaucratic impediments, have simpler/more direct processes, and have flexible common/statutory law providing allowance for better reviewing and penalty implementation. An animal experimentacion as a teaching resource contributes to the process of teaching-learning in bioethics for undergraduate students or

The European Partnership for Alternative Approaches to Animal Testing (EPAA) Directiva

\*, Claudia C. Calzada-Mendoza1

1 Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomás,

2 Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomás, México City, México

\*Address all correspondence to: languianorobledo@yahoo.com.mx

, Cornelio Barrientos-Alvarado2

university students.

162 Reflections on Bioethics

**Conflict of interest**

**Nomenclature**

3Rs principles

2010/63/EU

Directiva 2010/63 UE Real Decreto 53/2013

Normativa D2010/63/EU

Nanomaterials (NMs)

**Author details**

Liliana Anguiano-Robledo1

European Directive 2010/63/EU

Positron emission tomography (PET)

and María Elena Hernández-Campos1

Guidelines (OECD TG 407 and 408)

The principles of Good Laboratory Practice (GLP)

Functional magnetic resonance imaging (fMRI)

Delegación Miguel Hidalgo, México City, México

All coauthors declare no conflict of interest.


[12] Garner JP. The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? Institute for Laboratory Animal Research Journal. 2014;**55**(3):438-456. DOI: 10.1093/ilar/ilu047

[24] Vinardell MP. Alternativas a los animales de laboratorio en docencia. Revista de Toxicología. 2014, julio-diciembre;**31**:(2):124-129. Available from: http://www.redalyc.

Alternatives to Animal Experimentation: Its Institutional Teaching and Scientific

http://dx.doi.org/10.5772/intechopen.74941

165

[25] Hunt MJ, Macaskill AC. Student responses to active learning activities with live and virtual rats in psychology teaching laboratories. Teaching of Psychology. 2017, 1 April;

[26] Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung: Functions on a chip. Science (New York, N.Y.).

[27] Monteiro-Riviere NA, Inman AO, Snider TH, Blank JA, Hobson DW. Comparison of an in vitro skin model to normal human skin for dermatological research. Microscopy

[28] Kubilus J, Hayden PJ, Ayehunie S, Lamore SD, Servattalab C, Bellavance KL, et al. Full thickness EpiDerm: A dermal-epidermal skin model to study epithelial mesenchymal

interactions. ATLA: Alternatives to Laboratory Animals. 2004;**32**(Suppl 1A):75-82 [29] Auxenfans C, Fradette J, Lequeux C, Germain L, Kinikoglu B, Bechetoille N, et al. Evolution of three dimensional skin equivalent models reconstructed in vitro by tissue

[30] Semlin L, Schafer-Korting M, Borelli C, Korting HC. In vitro models for human skin

[31] Cheluvappa R, Jamieson HA, Hilmer SN, Muller M, Le Couteur DG. The effect of Pseudomonas aeruginosa virulence factor, pyocyanin, on the liver sinusoidal endothe-

[32] Cheluvappa R, Cogger VC, Kwun SY, O'Reilly JN, Le Couteur DG, Hilmer SN. Liver sinusoidal endothelial cells and acute non-oxidative hepatic injury induced by Pseudomonas aeruginosa pyocyanin. International Journal of Experimental Pathology. 2008;**89**:410-418

[33] Johnston HJ, Verdon R, Gillies S, Brown DM, Fernandes TF, Henry TB, Rossi AG, Tran L, Tucker C, Tyler CR, Stone V. Adoption of in vitro systems and zebrafish embryos as alternative models for reducing rodent use in assessments of immunological and oxidative stress responses to nanomaterials. Critical Reviews in Toxicology. 2017, Dec;**4**:1-20.

[34] Martonen T, Fleming J, Schroeter J, Conway J, Hwang D. In silico modeling of asthma.

[35] Golbamaki A, Cassano A, Lombardo A, Moggio Y, Colafranceschi M, Benfenati E. Comparison of in silico models for prediction of Daphnia magna acute toxicity. SAR and

[36] Raunio H, Taavitsainen P, Honkakoski P, Juvonen R, Pelkonen O. In vitro methods in the prediction of kinetics of drugs: Focus on drug metabolism. ATLA—Alternatives to

lial cell. Journal of Gastroenterology and Hepatology. 2007c;**22**:1350-1351

engineering. European Journal of Dermatology. 2009;**19**:107-113

org/articulo.oa?id=91932969014

2010;**328**:1662-1668

**44**(2):160-164. DOI: 10.1177/0098628317692632

Research and Technique. 1997;**37**:172-179

disease. Drug Discovery Today. 2011;**16**:132-139

DOI: 10.1080/10408444.2017.1404965

Laboratory Animals. 2004;**32**:425-430

Advanced Drug Delivery Reviews. 2003;**55**:829-849

QSAR in Environmental Research. 2014;**25**:673-694


[24] Vinardell MP. Alternativas a los animales de laboratorio en docencia. Revista de Toxicología. 2014, julio-diciembre;**31**:(2):124-129. Available from: http://www.redalyc. org/articulo.oa?id=91932969014

[12] Garner JP. The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? Institute for Laboratory

[13] Davidson MK, Lindsey JR, Davis JK. Requirements and selection of an animal model.

[14] Johnson PD, Besselsen DG. Practical aspects of experimental design in animal research. Institute for Laboratory Animal Research Journal. 2002;**43**(4):202-206. DOI: 10.1093/ ilar.43.4.202. Available from: http://www.oxfordjournals.org/our\_journals/ilarjournal/

[15] Festing MFW. Warning: The use of heterogeneous mice may seriously damage your research. Neurobiology of Aging. 1999;**20**(2):237-244. DOI: 10.1016/S0197-4580(99)00040-8

[16] Svendsen P, Hau J, editors. Handbook of Laboratory Animal Science. Vol. 2. Animal

[17] Cheluvappa R, Scowen P, Eri R. Ethics of animal research in human disease remediation, its institutional teaching; and alternatives to animal experimentation. Pharmacology Research and Perspectives. August 2017;**5**(4). Article number e00332. DOI: 10.1002/

[18] Cozigou G, Crozier J, Hendriksen C, Manou I, Ramirez-Hernandez T, Weissenhorn R. The European Partnership for alternative approaches to animal testing (EPAA): Promoting alternative methods in Europe and beyond. Journal of the American Association for Laboratory Animal Science. 2015;**54**(2):209-213. PubMed ID: 25836968 PMCID:PMC4382626. Available in: http://docserver.ingentaconnect.com/deliver/connect/aalas/15596109/v54n2/ s8.pdf?expires=1428111245&id=81370441&titleid=72010024&accname=Elsevier+BV&chec

[19] Laroche C, Lalis G, Brekelmans C. The European partnership for alternative approaches to animal testing. AATEX 14, Special Issue, 769-773. Proc. 6th World Congress on

Alternatives & Animal Use in the Life Sciences. Tokyo, Japan. August 21-25, 2007

[20] Repetto G. Recent advances on the validation and acceptance of in vivo and in vitro alternative methods | [RECIENTES AVANCES EN LA VALIDACION Y ACEPTACION DE METODOS ALTERNATIVOS IN VIVO E IN VITRO]. Revista de Toxicología.

[21] Cooper-Hannan R. Good laboratory practice and study management for the validation of in vitro toxicity studies. ATLA Alternatives to Laboratory Animals. 1997,

[22] Repetto G, Älvarez Herrera C, del Peso A. Estrategias de identificación de planteamientos alternativos a la experimentación animal. Revista de Toxicología. 2014;**31**:108-114. Available from: Disponible en: http://www.redalyc.org/articulo.oa?id=91932969002

[23] Castaño A, Repetto G. Métodos alternativos, Capítulo 25. In: Martín Zúñiga J, Nora S, editors. Generalidades. En Ciencia y Tecnología en protección y experimentación ani-

Animal Research Journal. 2014;**55**(3):438-456. DOI: 10.1093/ilar/ilu047

Models. Boca Raton, Florida: CRC PRES; 1944

ksum=F5F53664D823A1C44F53142E642AE639

September;**25**(5):527-537 ISSN: 02611929

mal. Spain: Universidad de Alcalá; 2009

prp2.332

164 Reflections on Bioethics

1995;**12**(1):3-9

Israel Journal of Medical Sciences. 1987,Jun;**23**(6):551-555. PMID:3312096


[37] van Leeuwen K, Schultz TW, Henry T, Diderich B, Veith GD. Using chemical categories to fill data gaps in hazard assessment. SAR and QSAR in Environmental Research. 2009;**20**:207-220

**Section 5**

**Selected Topics of Bioethics**

